<DOC>
	<DOCNO>NCT00005078</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine tirapazamine , carboplatin , paclitaxel treat patient advanced malignant solid tumor .</brief_summary>
	<brief_title>Tirapazamine , Carboplatin , Paclitaxel Treating Patients With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose tirapazamine combination carboplatin paclitaxel patient advance solid tumor receive prior chemotherapy . - Assess toxicity preliminary efficacy regimen patient . - Determine pharmacokinetic profile regimen patient . - Investigate potential predictor response study patient tissue specimens receive regimen . OUTLINE : This dose-escalation study tirapazamine . Patients stratify accord prior chemotherapy status ( previously untreated v previously treat ) . Patients receive tirapazamine IV 2 hour , paclitaxel IV 3 hour , carboplatin IV 30 minute . Treatment continue every 21 day maximum 8 course absence unacceptable toxicity disease progression . Some patient may continue therapy absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tirapazamine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 12 patient previously untreated stratum treat MTD . Patients follow indefinitely . PROJECTED ACCRUAL : A total 36-68 patient ( 18-34 per stratum ) accrue study within 12-18 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic malignant solid tumor curable resection standard therapy No symptomatic brain metastasis Brain metastasis allow provide controlled surgical excision and/or radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal Renal : Creatinine normal Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV congestive heart failure Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No history allergic reaction appropriate diuretic antiemetic administer conjunction protocol chemotherapy ( e.g. , 5HT3 antagonist ) No concurrent uncontrolled illness would preclude study therapy No medical , social , psychological factor would preclude study therapy No clinically significant hearing loss PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No 2 prior chemotherapy regimens No prior combination paclitaxel carboplatin Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Other : At least 30 day since prior investigational drug No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>